JP2017510572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510572A5 JP2017510572A5 JP2016556962A JP2016556962A JP2017510572A5 JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5 JP 2016556962 A JP2016556962 A JP 2016556962A JP 2016556962 A JP2016556962 A JP 2016556962A JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aliphatic
- present
- alkyl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C1C*c2cc(*)c(C=CC(C=*)=CC=C*)c(*)c2)ON=C1c1c(*)cccc1* Chemical compound *C(C1C*c2cc(*)c(C=CC(C=*)=CC=C*)c(*)c2)ON=C1c1c(*)cccc1* 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952754P | 2014-03-13 | 2014-03-13 | |
| US61/952,754 | 2014-03-13 | ||
| US201462061463P | 2014-10-08 | 2014-10-08 | |
| US62/061,463 | 2014-10-08 | ||
| PCT/US2015/020582 WO2015138986A1 (en) | 2014-03-13 | 2015-03-13 | Fxr agonists and methods for making and using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510572A JP2017510572A (ja) | 2017-04-13 |
| JP2017510572A5 true JP2017510572A5 (enExample) | 2017-06-29 |
Family
ID=54072502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556962A Pending JP2017510572A (ja) | 2014-03-13 | 2015-03-13 | Ｆｘｒアゴニストならびに作製および使用のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3116878A4 (enExample) |
| JP (1) | JP2017510572A (enExample) |
| KR (1) | KR20160132111A (enExample) |
| AU (1) | AU2015229072A1 (enExample) |
| CA (1) | CA2942403A1 (enExample) |
| WO (1) | WO2015138986A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| CA2956163C (en) | 2014-07-24 | 2023-01-10 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
| EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2017078928A1 (en) * | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| PE20190972A1 (es) * | 2016-09-14 | 2019-07-09 | Novartis Ag | Combinacion de agonistas de fxr |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| EP3852748B1 (en) | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| TW202114672A (zh) | 2019-07-23 | 2021-04-16 | 瑞士商諾華公司 | 使用fxr促效劑的肝臟疾病之組合治療 |
| WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
| KR20220054608A (ko) | 2019-09-03 | 2022-05-03 | 노파르티스 아게 | ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제 |
| JP2022548617A (ja) | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む処置 |
| CN114502198A (zh) | 2019-09-30 | 2022-05-13 | 诺华股份有限公司 | 包括使用fxr激动剂的治疗 |
| EP4076454A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Combination treatment of liver diseases using integrin inhibitors |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| CN120227340A (zh) | 2020-03-18 | 2025-07-01 | 伊莱利利公司 | 法尼醇x受体激动剂的制剂 |
| JP7664278B2 (ja) | 2020-03-18 | 2025-04-17 | オルガノボ，インク． | ファルネソイドｘ受容体アゴニストの結晶質形態 |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
| CN120698876B (zh) * | 2025-06-03 | 2026-06-09 | 上海埃思凯特科技有限公司 | 一种吉非罗齐氘代衍生物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| WO2007070796A1 (en) * | 2005-12-15 | 2007-06-21 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US20080300235A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20090163474A1 (en) * | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| JP2012503654A (ja) * | 2008-09-26 | 2012-02-09 | ワイス・エルエルシー | １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤 |
| EP4137137A1 (en) * | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| JP2014521699A (ja) * | 2011-08-04 | 2014-08-28 | ルメナ ファーマシューティカルズ，インク． | 膵臓炎の処置用の胆汁酸再利用阻害剤 |
-
2015
- 2015-03-13 CA CA2942403A patent/CA2942403A1/en not_active Abandoned
- 2015-03-13 JP JP2016556962A patent/JP2017510572A/ja active Pending
- 2015-03-13 KR KR1020167028569A patent/KR20160132111A/ko not_active Withdrawn
- 2015-03-13 WO PCT/US2015/020582 patent/WO2015138986A1/en not_active Ceased
- 2015-03-13 EP EP15761517.0A patent/EP3116878A4/en not_active Withdrawn
- 2015-03-13 AU AU2015229072A patent/AU2015229072A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015138986A1 (en) | Fxr agonists and methods for making and using | |
| JP7665619B2 (ja) | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 | |
| TWI358296B (en) | Acid secretion inhibitor | |
| CN113056271B (zh) | 法尼醇x受体激动剂及其用途 | |
| JP6632532B2 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
| CN113056264A (zh) | 法尼醇x受体激动剂及其用途 | |
| TW200900064A (en) | Pyrrole compounds | |
| WO2017078928A1 (en) | Fxr agonists and methods for making and using | |
| AU2015229055A1 (en) | Analogs of fexaramine and methods of making and using | |
| CN113056265A (zh) | 法尼醇x受体激动剂及其用途 | |
| JP6276760B2 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| WO2020061118A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| KR102433588B1 (ko) | 할로겐 치환 헤테로환 화합물의 염 | |
| EP2296659A2 (en) | Drug combinations comprising a dgat inhibitor and a ppar-agonist | |
| TWI893238B (zh) | 二氯酚hsd17b13抑制劑及其用途 | |
| CN112955448A (zh) | 芳环或芳杂环类化合物及其制备方法和医药用途 | |
| AU2017293271A1 (en) | Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof | |
| IL189666A (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | |
| TW200920366A (en) | 5-membered heterocyclic compound | |
| CN104203236A (zh) | 杂环酰胺衍生物和含有其的药物 | |
| WO2010007943A1 (ja) | 含窒素複素環化合物 | |
| TW202304898A (zh) | 噻唑/異噻唑hsd17b13抑制劑及其用途 | |
| TW202337449A (zh) | 2-取代噻唑hsd17b13抑制劑及其用途 | |
| CA2470427A1 (en) | Compositions and methods for treating heart failure | |
| JP2005514432A5 (enExample) |